PixarBio Corp (PXRB)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:PixarBio Corp (PXRB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013371
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:34
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
PixarBio Corp (PixarBio), formerly BMP Holdings Inc., is a biotechnology company that develops novel neurological drug delivery systems for postsurgical pain, acute pain and chronic pain. The company focuses on the research and commercial development of targeted drug delivery systems, devices and biologics to treat Parkinson’s disease, epilepsy, pain and spinal cord injury. Its lead product platform, NeuroRelease, facilitated the sustained release of non-addictive and non-opiate drugs in post-operative, acute and chronic pain in pre-clinical models. It helps reduce pain signals without impeding locomotion signals. The company has offices in New Hampshire, New York and New Jersey, the US. PixarBio is headquartered in Medford, Massachusetts, the US.

PixarBio Corp (PXRB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
PixarBio Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
PixarBio Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
PixarBio Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
PixarBio Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
PixarBio Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
PixarBio Corp, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
PixarBio Raises USD7.2 Million in Venture Financing 11
Merger 12
BMP Holdings Merges with PixarBio in Reverse Merger Transaction 12
Equity Offering 13
PixarBio Raises USD0.8 Million in Financing 13
PixarBio Raises USD7.2 Million in Private Placement of Shares and Warrants 14
PixarBio Corp – Key Competitors 15
PixarBio Corp – Key Employees 16
PixarBio Corp – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Strategy And Business Planning 18
Dec 21, 2016: PixarBio Establishes the JP Reynolds Research Center in Woburn, MA to Advance In-house Research Portfolio in Epilepsy, Spinal Cord Injury, and Non-Addictive Pain Platform 18
Corporate Communications 19
Dec 20, 2016: PixarBio appoints new COO 19
Jul 11, 2016: World Renowned Entrepreneur Laura Morse Joins PixarBio’s Board of Directors as PixarBio Prepares for SEC Compliance 20
Feb 22, 2016: PixarBio Turns Focus To Commercialization in 2018 for NeuroRelease a Non Opiate, Non Addictive Pain Treatment, Adding Industry Sales Veteran Taunia Markvicka as Chief Commercial Officer 21
Product News 22
12/20/2016: PixarBio Names Steve Chartier Chief Operating Officer, To Lead Regulatory Affairs, CMC, and Clinical Studies for NeuroRelease a Morphine Replacement, Non Addictive Pain Treatment 22
10/20/2016: PixarBio Expands PPM to $40,000,000, Extends PPM One Week to Close October 28, 2016 and Promotes Ken Stromsland to Vice President, CIO & External Communications 23
10/17/2016: PixarBio Discusses NeuroRelease a Non-Addictive Morphine Replacement at the 2016 SeeThruEquity Conference in New York City on October 17, 2016 24
10/13/2016: PixarBio Co-Founder and MIT Professor Dr. Robert S. Langer to Discuss the Evolution of NeuroRelease, a Non-Opiate and Non-Addictive Morphine Replacement 25
09/15/2016: PixarBio CEO Frank Reynolds to Present NeuroRelease a Non-Addictive Morphine Replacement at the 2016 Aegis Capital Growth Conference in Las Vegas, NV on September 21, 2016 26
06/27/2016: PixarBio Promotes David Kaplan to Chief Commercial Officer, as NeuroRelease a Morphine Strength Non Addictive Pain Treatment Remains on Track for 2018 Launch 27
03/30/2016: PixarBio, the Developers of NeuroRelease A Revolutionary Morphine Strength, Non-Addictive Pain Treatment Appoints Glenn Reiser Vice President of External Affairs 28
03/03/2016: PixarBio’s Dr. Taunia Markvicka and Glenn Reiser to Discuss Breakthrough Data on Morphine Strength Non-Addictive Pain Treatment NeuroRelease at the 2016 Congress of Neurological Surgeons Spine Summit held in Orlando, FL March 17-18, 2016 29
01/27/2017: PixarBio CEO Frank Reynolds to Present NeuroRelease a Morphine Replacement, Non-Opiate, Non Addictive Pain Treatment at the 2017 NobleCon13 Investor Conference in Boca Raton, FL on Monday, January 30, 2017 30
01/09/2017: PixarBio Expands Non-Opiate R&D Portfolio For Pain with Steroid Injections; Collaborates for Clinical cGMP Manufacturing, and Grooms Team For Clinical Studies of NeuroRelease Post-Surgical Pain Treatments 14-Day, 7-Day, and 3-Day 31
01/05/2017: PixarBio CEO Frank Reynolds to Present NeuroRelease a Morphine Replacement, Non-Opiate, Non Addictive Pain Treatment at the 2017 Biotech Showcase in San Francisco 32
Product Approvals 33
Mar 18, 2016: PixarBio Announces USFDA OPD Submission of NeuroRelease SCI for Orphan Drug Designation for Spinal Cord Injury 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
PixarBio Corp, Pharmaceuticals & Healthcare, Key Facts 2
PixarBio Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
PixarBio Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
PixarBio Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
PixarBio Corp, Deals By Therapy Area, 2011 to YTD 2017 9
PixarBio Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
PixarBio Raises USD7.2 Million in Venture Financing 11
BMP Holdings Merges with PixarBio in Reverse Merger Transaction 12
PixarBio Raises USD0.8 Million in Financing 13
PixarBio Raises USD7.2 Million in Private Placement of Shares and Warrants 14
PixarBio Corp, Key Competitors 15
PixarBio Corp, Key Employees 16
PixarBio Corp, Other Locations 17
PixarBio Corp, Subsidiaries 17

★海外企業調査レポート[PixarBio Corp (PXRB)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Imugene Ltd (IMU):製薬・医療:M&Aディール及び事業提携情報
    Summary Imugene Ltd (Imugene) is a clinical stage biopharmaceutical company which researches and develops vaccines in the area of immune-oncology. The company focuses on developing immunotherapies for the treatment of HER-2+ gastric and breast cancer. The HER-2 receptor works on surface of various t …
  • Physicians Endoscopy LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Physicians Endoscopy LLC (Physicians Endoscopy) is a provider of development and management of freestanding, single-specialty endoscopic ASCs. The company offers services such as design and development, professional management, billing and collections, and physician recruiting services. Its …
  • Agilvax Inc-製薬・医療分野:企業M&A・提携分析
    Summary Agilvax Inc (Agilvax) is a drug company that discovers and develops vaccines against infectious diseases and immunotherapies to treat cancer. The company develops products based on a proprietary virus-like particle platform technology. It develops immunotherapies to treat breast cancer, lung …
  • Intracom Holdings S.A. (INTRK):企業の財務・戦略的SWOT分析
    Intracom Holdings S.A. (INTRK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Glycotope GmbH-製薬・医療分野:企業M&A・提携分析
    Summary Glycotope GmbH (Glycotope) is a biopharmaceutical company that develops immuno-oncology products for the treatment of various types of cancer. The company’s expression platform offers proprietary technologies such as Glycobody (GET) and GlycoExpress(GEX) that allows the glycosylation of anti …
  • The Mosaic Company:企業の戦略・SWOT・財務分析
    The Mosaic Company - Strategy, SWOT and Corporate Finance Report Summary The Mosaic Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • VentiRx Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary VentiRx Pharmaceuticals Inc (VentiRx) is a biopharmaceutical company that develops and commercializes drugs for the treatment of respiratory, autoimmune diseases and cancer. The company develops toll like receptor 8 agonist and antagonists for the treatment of cancer, respiratory and autoimm …
  • Hollard Insurance Group:企業の戦略・SWOT・財務分析
    Hollard Insurance Group - Strategy, SWOT and Corporate Finance Report Summary Hollard Insurance Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Daito Trust Construction Co., Ltd.
    Daito Trust Construction Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Daito Trust Construction Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Trent Limited (TRENT):企業の財務・戦略的SWOT分析
    Trent Limited (TRENT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Shanghai SECCO Petrochemical Co Ltd:企業の戦略的SWOT分析
    Shanghai SECCO Petrochemical Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • University of Aberdeen-製薬・医療分野:企業M&A・提携分析
    Summary University of Aberdeen (UOA) is an educational and research institution that offers undergraduate, graduate, postgraduate and research programs in a range of subjects. The university offers undergraduate and postgraduate courses in the areas of arts, creative arts, commerce, education, engin …
  • Just Energy Group Inc. (JE):企業の財務・戦略的SWOT分析
    Just Energy Group Inc. (JE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Suning.com Co., Ltd. (002024):企業の財務・戦略的SWOT分析
    Suning.com Co., Ltd. (002024) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Catholic Health Initiatives:企業のM&A・事業提携・投資動向
    Catholic Health Initiatives - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Catholic Health Initiatives Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • ASIT Biotech SA (ASIT):企業の財務・戦略的SWOT分析
    Summary ASIT Biotech SA (ASIT Biotech), formerly BioTech Tools SA is a clinical stage biopharmaceutical company that develops in-vitro and in-vivo biotech tools. The company develops and commercializes immunotherapy medicines for respiratory and food allergies using ASIT plus technology platform. It …
  • IntraLinks, Inc.:企業の戦略・SWOT・財務情報
    IntraLinks, Inc. - Strategy, SWOT and Corporate Finance Report Summary IntraLinks, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Sc Arcada Con Srl:企業の戦略的SWOT分析
    Sc Arcada Con Srl - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • iCAD Inc (ICAD):医療機器:M&Aディール及び事業提携情報
    Summary iCAD Inc (iCAD) develops and markets computer aided detection (CAD) solutions and workflow solutions for mammography (film-based, digital radiography (DR) and computed radiography (CR), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). iCAD products find application in detectio …
  • Air Liquide SA (AI):企業の財務・戦略的SWOT分析
    Air Liquide SA (AI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆